Unified platform combines protocol guidance and precision dosing to advance antimicrobial stewardship and improve both patient and economic outcomes

DoseMe, a global leader in model-informed precision dosing (MIPD) software and a portfolio company of Fairlong Capital, today announced the acquisition of Firstline, a leading clinical decision support platform utilized worldwide. Firstline enables clinicians to rapidly access local, evidence-based infectious disease treatment guidance, susceptibility patterns, and antimicrobial stewardship (AMS) resources. The combination of DoseMe and Firstline creates a single, connected experience from therapy selection through personalized dosing, giving clinicians a faster path to optimal care.

“Firstline is the perfect complement to DoseMe with proven value that provides impact on patient outcomes, hospital ecology, and combating antimicrobial resistance,” said Paul Edwards, CEO of DoseMe. “Together, we support AMS initiatives and speed up optimized patient care decisions by helping clinicians access local stewardship protocols and translate them directly into personalized precision dosing.”

Antibiotic-resistant infections drive a significant and rapidly rising burden for providers. These infections cost the U.S. healthcare system between $21 billion and $34 billion annually, driving more than 8 million excess hospital days. Health systems need integrated solutions, turning stewardship policy into actionable intelligence at the point of care.

“We're immensely proud to have built Firstline into an organization delivering clinical guidance globally to hospitals, governments and the World Health Organization,” said Dr. Michael Long, co-founder and Chief Clinical Officer of Firstline. “We're excited to see Firstline continue to flourish as part of the larger DoseMe organization.”

“The combination of DoseMe and Firstline advances the mission to address the full patient care continuum of personalized medicine. We look forward to the consolidated business’ continued growth, but most importantly to the profound impact this combination will have on the customer’s ability to improve patient care,” said David Neiman, Managing Partner at Fairlong Capital.

For more information, please contact hello@dosemehealth.com or press@firstline.org.

About DoseMe

DoseMe combines smart technology with science, leveraging clinically-validated PK/PD models, patient characteristics, drug concentrations, and genotype to accurately individualize a dose in seconds. The platform is HIPAA compliant and the only Bayesian dosing platform that is both HITRUST CSF R2 and ISO 13485 certified. For more information on successful applications of its products, DoseMeRx and DoseMe Analytics, visit https://doseme-rx.com/success-stories

About Firstline

Firstline is a mobile-first clinical decision support platform designed to make infectious disease protocols accessible to every clinician, anywhere. Trusted by leading healthcare organizations worldwide, Firstline reduces antibiotic overuse, improves adherence to stewardship guidance, and provides clinicians with fast, reliable access to local resistance data. For more information, visit: Firstline - Clinical Decision Support Platform

About Fairlong Capital LLC

Fairlong Capital is a middle-market private equity firm focused on value investments in partnership with institutional and strategic investors across a variety of industries. Fairlong partners with management teams to offer flexible capital solutions to companies across a variety of industries, including healthcare, technology, industrials, business & financial services, building and forest products, power and energy, among others.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251103817621/en/